Helix BioPharma makes two appointments
Jack Kay as chairman and Professor Kazimierz Roszkowski-Sliz as European Medical Director
Helix has also hired Professor Kazimierz Roszkowski-Śliż as European Medical Director, to provide critical oversight and direction for Helix’s upcoming European L-DOS47 clinical programme.
Kay has been a director of Helix since 2005. He has worked in the pharmaceutical industry for more than 45 years, and since 1995 has been president of Apotex.
Professor Roszkowski-Śliż is an expert in the field of lung disease and lung cancers, and is a director at the National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland, where he is also head of the clinical department.
You may also like
Design & Build
![Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics]()
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics
The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Research & Development
![Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine]()
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine
The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
Manufacturing
![Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month]()
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month
Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Manufacturing
![Making blister package integrity testing decisions that QA can use]()
Making blister package integrity testing decisions that QA can use
A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions
